GST 2.0 for Pharma: The 56th Council Drug and Device Reset

The 56th GST Council met on 3 September 2025 and notified a rate rationalisation for the pharmaceutical rate grid effective 22 September 2025. Every rate table across an integrated Indian pharmaceutical company’s API-plus-formulation-plus-device portfolio changed on that date — all drugs under HSN Chapter 30 headings 3003 and 3004 to a flat 5 percent (a rate cut for the bulk of the formulation portfolio, previously 12 percent for most 3004 items); life-saving oncology and HIV and TB and rare-disease schedules to nil rate; medical devices under HSN Chapter 90 headings 9018 to 9022 from 18 percent to 5 percent. The reconciliation exposure that follows the pivot is not the rate cut itself but the second-order consequences — the deepened Rule 89(5) inverted-duty refund cycle against 18 percent packaging inputs and 12 percent excipients, the fresh Rule 42 and Rule 43 common-credit reversal on the nil-rated life-saving portion, the continuing permanent block on Chapter 27 mineral-oil solvent ITC under Notification 09/2022-Central Tax (Rate) dated 13 July 2022, and a full rewrite of the GSTR-1 and GSTR-3B rate-line tally for every tax period from September 2025 onwards. This is GST Council 56 pharma drugs medical devices 5 percent 22 September 2025 at operating scale, and the discipline that keeps the formulator’s Section 65 GST audit, its Form GST RFD-01 refund workbook, and its Rule 42/43 monthly reversal simultaneously clean is what separates a company that captures the Council FAQ Q10/Q25/Q51 expedited-refund posture from one that spends two quarters reworking its tax-period tally under a Section 74 notice.

Quick reference

The reconciliation in one paragraph

An integrated Indian pharmaceutical company — an API-plus-formulation-plus-device operation with a portfolio spanning HSN Chapter 29 (bulk drugs and antibiotics at heading 2941), HSN Chapter 30 (formulations at heading 3004 as finished dosage forms and heading 3003 as bulk drug mixtures), HSN Chapter 90 (medical instruments and diagnostic devices at headings 9018 to 9022), and a small life-saving oncology and HIV and TB sub-portfolio — must reconcile the 22 September 2025 pivot across three surfaces simultaneously. Surface 1 is the straddle-invoice window on the cutover date. Invoices dated on or before 21 September 2025 use the pre-pivot rate grid; invoices dated on or after 22 September 2025 use the new grid. Section 15 of the CGST Act 2017 fixes time of supply for goods, and the invoice date interacts with the dispatch and receipt dates to determine the applicable rate on a dispatch-20-September, receive-25-September straddle transaction. Surface 2 is the Rule 89(5) inverted-duty refund workbook. Pre-pivot, a 12 percent output against an 18 percent packaging input carried a 6 percentage-point inversion; post-pivot, a 5 percent output against the same 18 percent packaging input carries a 13 percentage-point inversion — more than double the pre-pivot exposure. Rule 89(5) as amended by Notification 14/2022-Central Tax dated 5 July 2022 gives the operational formula (Maximum Refund = (Turnover of inverted-rated supply × Net ITC / Adjusted Total Turnover) minus (Tax payable on inverted-rated supply × Net ITC / ITC availed on inputs and input services), with Net ITC excluding input services and capital goods per the Supreme Court in Union of India v. VKC Footsteps). Surface 3 is the Rule 42 and Rule 43 common-credit reversal on the nil-rated life-saving sub-portfolio, computed monthly as (Exempt turnover / Total turnover) × Common credit pool and true-up annually in the September following the financial year. The reconciliation base is a single unified purchase and sales register keyed to invoice date, HSN heading, rate, and (for the shared input pool) an exempt-supply attribution flag.

What the scenario looks like in India — an illustrative Sun Pharmaceutical Industries persona

The 56th GST Council pivot touches every large integrated Indian pharmaceutical company, and the reconciliation shape is largely uniform across the peer group. Illustrative Tier 1 integrated formulator-plus-API operators of the scale relevant to this pivot include Sun Pharmaceutical Industries (with its API and formulation manufacturing footprint across Halol in Gujarat, Ahmednagar in Maharashtra, and the historical Baddi plant network in Himachal Pradesh, plus its regulated-market Monroe, New Jersey plant), Dr Reddy’s Laboratories (Bachupally and Bollaram hubs in Hyderabad), Cipla (Kurkumbh in Maharashtra and Verna in Goa), Aurobindo Pharma (Hyderabad and Vishakhapatnam), Lupin (Ankleshwar in Gujarat and Aurangabad in Maharashtra), Zydus Lifesciences (Ahmedabad-Vadodara corridor), Torrent Pharmaceuticals, Alkem Laboratories, Glenmark Pharmaceuticals, and Cadila Pharmaceuticals. Tier 2 biosimilars and speciality and API-specialist operators with a parallel reconciliation shape include Biocon Biologics (as the Biocon subsidiary), Divi’s Laboratories (as one of the largest India-based API and intermediate manufacturers), Piramal Pharma, Ipca Laboratories, Ajanta Pharma, Suven Pharmaceuticals, Neuland Laboratories, Natco Pharma, Laurus Labs, Granules India, Strides Pharma Science, and JB Chemicals and Pharmaceuticals. The medical devices sub-portfolio (HSN 9018 to 9022) is dominated by companies such as Poly Medicure, HLL Lifecare, and Wockhardt’s device arm.

The reference persona for this article — assembled from public disclosures on the shape of a Tier 1 integrated formulator’s portfolio — is Sun Pharmaceutical Industries’ domestic formulation and API and device combined business. The portfolio splits illustratively into approximately 85 percent formulations under HSN 3003 and 3004 (the bulk of the volume), approximately 10 percent medical devices under HSN 9018 to 9022 (the device and diagnostic arm), and approximately 5 percent life-saving oncology under the Council-notified nil-rate schedule. The FY 2026-27 Q3 domestic pharma revenue at the illustrative persona’s scale runs at approximately Rs 3,200 crore (this figure is illustrative and cross-verifiable against the company’s annual report — the shape not the exact quantum is what carries the reconciliation logic).

Input-side, the portfolio consumes APIs at 5 percent under HSN Chapter 29 (bulk drugs from third-party manufacturers, from captive backward integration, or under a Section 92BA specified-domestic-transaction transfer from a subsidiary API plant), reaction and recrystallisation solvents at 18 percent under HSN Chapter 27 (hexane for extraction, isopropyl alcohol for recrystallisation, methanol for chromatography, toluene for aromatic reactions, methyl ethyl ketone for polar aprotic reactions) — these solvents are permanently blocked from Section 54(3) refund per Notification 09/2022-Central Tax (Rate), packaging inputs at 18 percent under HSN 3919 and 3920 and 3923 (polymer films and blister foils), HSN 4811 (laminated foils for strip-pack and blister-pack), HSN 4819 (corrugated cartons), and HSN 7607 (aluminium foil for blister packs), and excipients at 5 to 12 percent under HSN 3808 and 2915 and 2917 (starch derivatives, cellulose ethers, magnesium stearate, colouring and flavouring agents). The single-plant loan-licensee model — where a Tier 1 formulator sends inputs to a third-party manufacturer under Section 143 CGST plus Rule 45 CGST for job-work without payment of tax and the finished formulation is returned within one year (three years for capital goods) — layers a Form ITC-04 quarterly return reconciliation on top of the base surface, particularly where the loan-licensee is MSME-registered and Section 43B(h)‘s 45-day payment rule applies.

The regulatory overlay — Council notification, Section 54(3), Rule 89(5), Notification 09/2022, and Rule 42/43

Five regulatory anchors govern the pharmaceutical rate pivot and each maps to a specific reconciliation surface.

The 56th GST Council meeting on 3 September 2025 notified the rate rationalisation with effective date 22 September 2025. The Council FAQ document — question 10 addresses the collapse of the formulation rate grid to a flat 5 percent; question 25 addresses the deepening of the inverted duty structure and the Council’s pledge to expedite Section 54(3) refund processing; question 51 references the CBIC directive on Form GST RFD-01 processing timelines for pharmaceutical inverted-duty claims filed post 22 September 2025. The Council FAQ is not a statutory instrument but is treated in officer review as a reliable clarification of the Council’s intent on the rate reset and the refund posture. Reconciliation discipline requires the formulator to file the pre-pivot rate for invoices dated on or before 21 September 2025 and the post-pivot rate for invoices dated on or after 22 September 2025 — the cutover audit trail is the primary defence in a straddle-invoice officer question.

Section 54(3) of the CGST Act 2017 permits a registered person to claim a refund of unutilised input tax credit where the credit has accumulated on account of the rate of tax on inputs being higher than the rate of tax on output supplies — the inverted duty structure. The Supreme Court in Union of India v. VKC Footsteps India Pvt Ltd (2021) 10 SCC 674 upheld the statutory framework and confirmed that the refund is confined to unutilised credit on inputs; input services and capital goods are excluded. The first proviso to Section 54(3) permits the Central Government by notification to specify goods or services on which inverted-duty refund shall not be available — the statutory hook for Notification 09/2022.

Rule 89(5) of the CGST Rules 2017, as amended by Notification 14/2022-Central Tax dated 5 July 2022, provides the operational formula. Maximum Refund Amount = (Turnover of inverted-rated supply of goods and services × Net ITC / Adjusted Total Turnover) minus (Tax payable on such inverted-rated supply × Net ITC / ITC availed on inputs and input services). Net ITC excludes input services and capital goods. The 5 July 2022 amendment applies prospectively — refund applications filed on or after 5 July 2022 use the amended formula; earlier applications are governed by the pre-amendment formula. For a pharma formulator post 22 September 2025, the inversion arises structurally because formulations under HSN 3003 and 3004 attract 5 percent output GST and the packaging inputs under HSN 3919 through 3923, HSN 4811, HSN 4819, and HSN 7607 all attract 18 percent input GST — a 13 percentage-point inversion on the packaging component of every finished pack. Excipients under HSN 3808 and 2915 at 12 percent inject a 7 percentage-point inversion on the excipient bill. The refund is filed monthly on Form GST RFD-01 against the accumulated inverted-duty credit.

Notification 09/2022-Central Tax (Rate) dated 13 July 2022 and effective 18 July 2022 invokes clause (ii) of the first proviso to Section 54(3) and bars Section 54(3) inverted-duty refund for goods under HSN Chapter 15 (edible fats and oils — the anchor for the Agro Processing edible-oil scenario at the edible oil Chapter 15 IDR refund blocked under Notification 09/2022 explainer) and HSN Chapter 27 (mineral fuels, mineral oils, distillation products — this is the block that hurts API manufacturers, because hexane under HSN 2707/2710, isopropyl alcohol under HSN 2905, methanol under HSN 2905, toluene under HSN 2707/2902, and methyl ethyl ketone under HSN 2914 are all Chapter 27 or Chapter 29 depending on classification, but the notification specifically targets the mineral-oil derivatives that dominate API solvent use). The bar is permanent and structural, not a rate correction — the Council did not lift the block in the 22 September 2025 pivot, and the API manufacturer’s solvent ITC accumulates in the electronic credit ledger indefinitely (a cash-flow tax) or is expensed to the cost of API. Reconciliation discipline requires the API bill of material to split solvent inputs (Chapter 27, blocked) from reagent inputs (Chapter 29, refundable) so the refund workbook does not accidentally include the blocked slice.

Rules 42 and 43 of the CGST Rules 2017 govern common-credit apportionment and reversal where the same input is used for taxable and exempt supplies. Nil-rated life-saving drugs on the Council-notified schedule are exempt for common-credit purposes. Rule 42 requires monthly reversal of ITC on inputs and input services attributable to exempt supplies, computed as (Exempt turnover / Total turnover) × Common credit pool. Rule 43 requires the same reversal for capital-goods ITC, spread over the sixty-month capital-goods life. The annual true-up runs in the September following the financial year. A formulator with a shared API and packaging input pool used for both taxable formulations (5 percent) and exempt life-saving formulations (nil) must reverse the exempt-attributable portion of the shared ITC before filing the Rule 89(5) refund on the taxable-attributable portion — the two computations draw from mutually exclusive slices of the same pool.

A worked example — a Tier 1 integrated formulator at Q3 FY 2026-27 close

Illustrative — the following figures represent the operating pattern of a Tier 1 Indian integrated formulator at the scale a listed group discloses in quarterly filings. Public disclosures do not reveal per-SKU rate-line ITC detail; cross-verify against your own GSTR-3B extract and Rule 89(5) refund workbook before action.

A Tier 1 integrated formulator closes its books on 31 December 2026 with FY 2026-27 Q3 domestic pharma revenue of approximately Rs 3,200 crore, split illustratively into approximately Rs 2,720 crore of formulations under HSN 3003 and 3004 at 5 percent output GST (85 percent of the quarter), approximately Rs 320 crore of medical devices under HSN 9018 to 9022 at 5 percent output GST (10 percent), and approximately Rs 160 crore of nil-rated life-saving oncology under the Council schedule (5 percent). Output GST on the taxable portion (Rs 3,040 crore combined at 5 percent) is Rs 152 crore for the quarter.

The input side for the same quarter — again illustrative — is approximately Rs 480 crore of APIs at 5 percent input GST (Rs 24 crore ITC), approximately Rs 165 crore of packaging inputs at 18 percent input GST (Rs 29.7 crore ITC), approximately Rs 92 crore of excipients at 12 percent input GST (Rs 11.04 crore ITC), approximately Rs 78 crore of Chapter 27 solvents at 18 percent input GST (Rs 14.04 crore ITC — permanently blocked from Section 54(3) refund per Notification 09/2022 and either sitting unutilised or expensed to the cost of API), and approximately Rs 210 crore of input services and capital goods at 18 percent input GST (Rs 37.8 crore ITC — excluded from the Rule 89(5) Net ITC per the amended formula).

Applying the Rule 89(5) formula on the eligible Net ITC of Rs 64.74 crore against the taxable output of Rs 3,040 crore and the exempt output of Rs 160 crore (total turnover Rs 3,200 crore), the first-limb ratio (Turnover of inverted-rated supply / Adjusted Total Turnover) attributes the refund to the inverted-rated slice only — the medical device and formulation portion, not the exempt life-saving portion. The second-limb ratio under the Notification 14/2022 amendment (Tax payable on inverted-rated supply × Net ITC / ITC availed on inputs and input services) narrows the refund further. The refund draft that comes out of the workbook is filed on Form GST RFD-01 monthly at approximately one-third of the quarterly base — the exact quantum depends on tax-period tallies against the GSTR-3B filing.

Separately, Rule 42 monthly reversal on the exempt life-saving portion is computed as (Rs 160 crore / Rs 3,200 crore) × Common credit pool. Applied to the shared API-and-packaging-and-excipient pool of Rs 64.74 crore Net ITC, the Rule 42 reversal for the quarter is approximately Rs 3.24 crore — reversed month by month with the September following-year true-up. Rule 43 reversal on the capital-goods portion of the shared pool follows the same ratio but spread over sixty months. The two computations must be run before the Rule 89(5) refund draft, because the exempt-attributable portion of the ITC pool cannot also be refunded — the workbook must draw Net ITC from the taxable-only slice.

The straddle-window reconciliation for the September 2025 cutover (relevant to any invoice bridging the 21-to-22 September boundary) is a one-time exercise for the tax period in which the cutover falls, but the audit trail — a sales and purchase invoice register split against the cutover date with the pre-pivot rate and post-pivot rate correctly attributed — is retained for the seven-year statutory record retention window and produced on any officer question on the tax-period tally.

Common reconciliation breakages

Five breakages recur across integrated Indian pharmaceutical operations running the 22 September 2025 pivot, and each maps to a specific control failure.

• Straddle-window rate mis-attribution. Invoices dated on or before 21 September 2025 must use the pre-pivot rate grid; invoices on or after 22 September 2025 must use the new grid. Formulators that key the rate off dispatch date rather than invoice date, or that carry forward the pre-pivot rate on a September 2025 invoice by system default, mis-file the GSTR-1 rate-line tally and open a Section 73 (or 74 where mis-classification is deemed wilful) demand at the officer review of the tax period. The cutover audit trail — a split invoice register with the invoice date, dispatch date, receipt date, and rate correctly attributed under Section 15 time of supply — is the primary defence.

• Rule 89(5) Net ITC over-inclusion. The formulator continues to include input services (freight, machine maintenance, consulting) and capital-goods ITC (packaging machinery, pasteurisers, laboratory instruments) in the Net ITC numerator of the Rule 89(5) formula. This was expressly excluded by Notification 14/2022 dated 5 July 2022 and by the Supreme Court in Union of India v. VKC Footsteps India Pvt Ltd (2021) 10 SCC 674. Refund claims filed on the over-inclusive basis are either rejected by the proper officer at the RFD-01 processing stage or partly disallowed after audit, and the excess claim triggers Section 74 penalty exposure at year-end. Reconciliation discipline requires the input-services ledger and the capital-goods ledger to be separated from the raw-material and packaging ledger at source, so the Net ITC ratio in the refund formula draws only from the eligible base.

• Chapter 27 solvent ITC mis-claim. An API manufacturer that uses hexane, isopropyl alcohol, methanol, toluene, or methyl ethyl ketone as reaction and recrystallisation solvents pays 18 percent input GST on the solvent bill. Notification 09/2022-Central Tax (Rate) permanently bars that ITC from Section 54(3) refund. Formulators that treat the solvent ITC as refundable — either because the internal tax team confuses the pharma pivot (which cut the output rate) with an unblocking of solvent ITC (which did not happen) or because the ERP master fails to flag the Chapter 27 HSN class as blocked — file an inflated RFD-01 that is rejected on officer review and triggers a Section 74 excess-claim penalty. The same blockage applies to Chapter 15 edible-oil ITC and the mechanic is documented at edible oil Chapter 15 IDR refund blocked under Notification 09/2022 for the FMCG parallel.

• Rule 42/43 reversal missed on nil-rated life-saving portion. The 5 percent-to-nil rate cut for the Council-notified life-saving schedule (oncology, HIV, TB, rare-disease) is presented in the Council FAQ as a customer-facing benefit, but it creates a fresh Rule 42 and Rule 43 common-credit reversal exposure on the formulator’s shared input pool. Formulators that continue to claim full ITC on the shared API and packaging pool without reversing the exempt-attributable portion under-reverse by (Exempt turnover / Total turnover) × Common credit pool every month. The September following-year true-up surfaces the shortfall and the interest at Section 50 rates from the tax period of accrual is the penalty exposure.

• Loan-licensee ITC-04 reconciliation gap. Where the formulator uses a Section 143 CGST loan-licensee model — sending inputs to a third-party manufacturer under Rule 45 for job-work without payment of tax and receiving the finished formulation back within one year (three years for capital goods) — the Form ITC-04 quarterly return must reconcile the input dispatch, the finished-goods return, and any process loss or by-product. The 22 September 2025 pivot changes the rate on the returned finished goods (5 percent post-pivot versus 12 percent pre-pivot on 3004 items), and the loan-licensee reconciliation for the cutover window must correctly key the returned batch against the applicable rate. Where the loan-licensee is MSME-registered, the Section 43B(h) 45-day payment rule layers a further reconciliation surface on the job-work fee.

For a systematic method to catalogue these breakages against upstream data controls, the reconciliation failure mode analysis for India cornerstone sets out the design-layer discipline; for the operating cadence that carries the reversal, refund, and cutover reconciliations through the month-end and quarterly close, the reconciliation playbook for monthly close walkthrough covers the operating-layer discipline.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the sales invoice register split against the 22 September 2025 cutover date, the purchase invoice register split against the same cutover with HSN heading and rate correctly attributed, the input master with a Notification 09/2022 blocked-flag on Chapter 15 and Chapter 27 headings, the product master with a Council-schedule nil-rate flag on the life-saving sub-portfolio, the loan-licensee master with Section 143 dispatch and return tracking under Rule 45 for the Form ITC-04 return, and the GSTR-1 and GSTR-3B rate-line feeds from the tax-period filings — and produces a unified reconciliation pack that closes the loop from invoice-date rate attribution to Rule 89(5) refund draft to Rule 42/43 monthly reversal. The platform runs the straddle-window rate split under Section 15 time-of-supply logic on every cutover-adjacent invoice, computes the Rule 89(5) Net ITC on the eligible base only (input services and capital goods correctly excluded per Notification 14/2022 and Chapter 27 solvent ITC correctly excluded per Notification 09/2022), computes the Rule 42 monthly reversal on the shared common-credit pool against the exempt-supply ratio, and produces the Form GST RFD-01 refund draft against the accumulated inverted-duty credit per tax period. Match rate improvement of 51 to 88 percent on the tax-period rate-line reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling on AWS Mumbai, is what makes the platform the reconciliation base for a Tier 1 integrated formulator or a Tier 2 API-specialist finance team through the Council FAQ Q10/Q25/Q51 expedited-refund window.

Cross-cluster bridges and where to read next

The straddle-invoice window on the cutover is unpacked in detail at pharma inventory GST rate switch 22 September 2025 reconciliation — the SKU-level and batch-level cutover discipline. The medical device sub-portfolio’s move from 18 percent to 5 percent — the single largest rate cut in the pivot for a device-heavy portfolio — is walked through at medical device HSN 9018 to 9022 rate change. The life-saving nil-rate schedule and the Rule 42/43 reversal machinery it triggers is covered in life-saving drugs nil rate GST — cancer, HIV, TB, rare-disease. The Rule 89(5) refund workbook mechanics for the deepened inversion are detailed at Rule 89(5) inverted-duty refund for pharma formulations — complete guide. The Council FAQ document itself — questions 10, 25, and 51 that anchor the expedited-refund posture — is unpacked in GST Council FAQ Q10, Q25, Q51 pharma clarifications reading guide.

Cross-cluster, the Notification 09/2022 permanent block on inverted-duty refund is the identical mechanic that governs the Agro Processing edible-oil sub-cluster — the same notification, a different HSN chapter — walked through at edible oil Chapter 15 IDR refund blocked under Notification 09/2022. The Rule 89(5) refund cycle at the packaged-milk scale (5 percent output against 18 percent packaging input, before any deepening from the September 2025 pivot) is the Agro Processing parallel and is covered at dairy inverted-duty refund under Rule 89(5) post GST 2.0. The GSTR-2B ITC reconciliation surface that a formulator’s finance team runs every tax period — the vendor-side ITC reflection that the RFD-01 refund workbook draws from — is documented at GSTR-2B ITC reconciliation failure modes India. The TDS-side reconciliation for the Section 194Q / TDS payment code 1031 exposure on high-value API and intermediate purchases above the Rs 50 lakh single-supplier threshold sits at TDS payment code 1031, Section 393 Sl. 8 purchase of goods. The commercial pillar for the entire pharma sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India and the direct GST-side pillar is GST reconciliation software.

The five FAQs below address the operational questions Indian pharmaceutical controllers and tax leads ask most often when implementing the 22 September 2025 pivot reconciliation across the straddle window, the Rule 89(5) refund workbook, the Rule 42/43 common-credit reversal, and the continuing Chapter 27 solvent block.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 13 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024